Abstract
Newborn sepsis is a major cause of child mortality across the world. Strategies for prevention and treatment have the potential to save many newborns from a sepsis-related death. Among the various parenteral antibiotic options possible, there is considerable experience with the use of penicillins, cephalosporins, and aminoglycosides. Ciprofloxacin is also increasingly accepted as safe in the neonate. However, the available evidence is not of high quality, and adequate research is required to specifically address dosage schedules, safety, and efficacy of ciprofloxacin to lead to established interventions to reduce morbidity and mortality for neonatal sepsis.
| Original language | English |
|---|---|
| Pages (from-to) | 1019-1022 |
| Number of pages | 4 |
| Journal | Adverse Drug Reaction Bulletin |
| Issue number | 265 |
| DOIs | |
| Publication status | Published - Dec 2010 |
Fingerprint
ASJC Scopus subject areas
- Pharmacology
- Pharmacology (medical)
Cite this
Safety of ciprofloxacin in neonates with sepsis. / Bonati, Maurizio; Pandolfini, Chiara; Kaguelidou, Florentia; Jacqz-Aigrain, Evelyne; Turner, Mark; Choonara, Imti.
In: Adverse Drug Reaction Bulletin, No. 265, 12.2010, p. 1019-1022.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Safety of ciprofloxacin in neonates with sepsis
AU - Bonati, Maurizio
AU - Pandolfini, Chiara
AU - Kaguelidou, Florentia
AU - Jacqz-Aigrain, Evelyne
AU - Turner, Mark
AU - Choonara, Imti
PY - 2010/12
Y1 - 2010/12
N2 - Newborn sepsis is a major cause of child mortality across the world. Strategies for prevention and treatment have the potential to save many newborns from a sepsis-related death. Among the various parenteral antibiotic options possible, there is considerable experience with the use of penicillins, cephalosporins, and aminoglycosides. Ciprofloxacin is also increasingly accepted as safe in the neonate. However, the available evidence is not of high quality, and adequate research is required to specifically address dosage schedules, safety, and efficacy of ciprofloxacin to lead to established interventions to reduce morbidity and mortality for neonatal sepsis.
AB - Newborn sepsis is a major cause of child mortality across the world. Strategies for prevention and treatment have the potential to save many newborns from a sepsis-related death. Among the various parenteral antibiotic options possible, there is considerable experience with the use of penicillins, cephalosporins, and aminoglycosides. Ciprofloxacin is also increasingly accepted as safe in the neonate. However, the available evidence is not of high quality, and adequate research is required to specifically address dosage schedules, safety, and efficacy of ciprofloxacin to lead to established interventions to reduce morbidity and mortality for neonatal sepsis.
UR - http://www.scopus.com/inward/record.url?scp=78650433202&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78650433202&partnerID=8YFLogxK
U2 - 10.1097/FAD.0b013e328342564b
DO - 10.1097/FAD.0b013e328342564b
M3 - Article
AN - SCOPUS:78650433202
SP - 1019
EP - 1022
JO - Adverse Drug Reaction Bulletin
JF - Adverse Drug Reaction Bulletin
SN - 0044-6394
IS - 265
ER -